1. Homepage
  2. Equities
  3. Japan
  4. Japan Exchange
  5. Chugai Pharmaceutical Co., Ltd
  6. News
  7. Summary
    4519   JP3519400000

CHUGAI PHARMACEUTICAL CO., LTD

(4519)
  Report
Delayed Japan Exchange  -  05/20 02:00:00 am EDT
3536.00 JPY   +0.31%
05/18Judgement On The First Drug Patent Linkage Lawsuit In China Is Issued
AQ
04/28Chugai Pharmaceutical Co., Ltd. - Notice of Completion of Disposal of Treasury Shares as Restricted Stock Compensation Plan
AQ
04/27CHUGAI PHARMACEUTICAL : Notice of Completion of Disposal of Treasury Shares as Restricted Stock Compensation Plan
PU
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Chugai Obtained Highest A-Rating by CDP in Two Categories and SBT Validation for Greenhouse Gas Reduction Target

12/20/2021 | 10:04am EDT

TOKYO - Chugai Pharmaceutical Co., Ltd. (TOKYO: 4519) announced that the company was awarded the highest rating by a global environmental non-profit CDP, being placed on CDP's A-List in the two categories of climate change and water security. Chugai also announced that the Science Based Target (SBT) initiative validated the greenhouse gas reduction targets in Chugai's Mid-term Environmental Goals 2030, which demonstrate that the targets are consistent with the Paris Agreement goals.

CDP is a non-governmental organization (NGO) in the United Kingdom that was inaugurated in 2000. By sending out questionnaires to major companies around the world and encouraging information disclosure on their efforts to address environmental issues and evaluating them, CDP aims to enhance engagement in environmental issues worldwide. Chugai had started to participate in the reporting in 2012 and was rated 'A?' and 'B' for climate change and water security respectively in 2020. In 2020, Chugai expressed its endorsement with the recommendations of TCFD (Climate-Related Financial Disclosure Task Force) and identified material issues to establish new science-based medium-term environmental targets. Chugai believes that these continuous efforts and the company's information disclosure led to the results this year.

The SBT initiative is a partnership between four organizations: CDP, the United Nations Global Compact, World Resources Institute (WRI) and the World Wide Fund for Nature (WWF). It covers not only the direct emissions by the reporting company itself, but also the supply chain emissions from all types of emissions related to business activities. The greenhouse gas reduction targets validated this time are to reduce the total emissions of Scope 1 and Scope 2 by 60% by 2030 and reduce Scope 3 emissions by 30%, both compared to 2019*. As a longer-term goal, Chugai aims to achieve zero Scope 1 and Scope 2 emissions by 2050.

Scope1: Direct greenhouse gas emissions by the reporting company itself. (e.g. fuel combustion, industrial process). Scope2: Indirect emissions from the use of electricity, heat, or steam supplied by others. Scope3: Indirect emissions other than Scope 1 and Scope 2 (Emissions by others related to the company's activities)

In the growth strategy TOP I 2030, Chugai sets a 'role model for the world' as one of three visions as a top innovator in 2030, aiming to become a leader in resolving social issues by pursuing ESG initiatives through business activities. We will continue pursuing environmental measures in all aspects of our business activities to achieve sustainable growth together with the society.

Reference

Chugai's Sustainability: https://www.chugai-pharm.co.jp/english/sustainability/index.html

Mid-term Environmental Goals 2030: https://www.chugai-pharm.co.jp/english/sustainability/environment/action.html

Contact:

Media

Chugai Pharmaceutical Co., Ltd.

Media Relations Group

Corporate Communications Dept.

Tomoko Shimizu

Tel: +81-3-3273-0881

E-mail: pr@chugai-pharm.co.jp

Investors

Chugai Pharmaceutical Co., Ltd.

Investor Relations Group

Corporate Communications Dept.

Takayuki Sakurai

Tel: +81-3-3273-0554

E-mail: ir@chugai-pharm.co.jp

(C) 2021 Electronic News Publishing, source ENP Newswire

Stocks mentioned in the article
ChangeLast1st jan.
CHUGAI PHARMACEUTICAL CO., LTD 0.31% 3536 Delayed Quote.-5.33%
ROCHE HOLDING AG 0.88% 319.7 Delayed Quote.-15.67%
All news about CHUGAI PHARMACEUTICAL CO., LTD
05/18Judgement On The First Drug Patent Linkage Lawsuit In China Is Issued
AQ
04/28Chugai Pharmaceutical Co., Ltd. - Notice of Completion of Disposal of Treasury Shares a..
AQ
04/27CHUGAI PHARMACEUTICAL : Notice of Completion of Disposal of Treasury Shares as Restricted ..
PU
04/26CHUGAI PHARMACEUTICAL : Script (including Q&A)
PU
04/26Chugai Pharmaceutical Co., Ltd. - Organizational and Personnel Changes
AQ
04/26Nikkei 225 Up 0.4% on Wall Street Cues, Softer Interest Rates, Oil Outlook
MT
04/26Chugai Pharmaceutical Logs 178% Surge in Q1 Net Income on Higher Sales
MT
04/25CHUGAI PHARMACEUTICAL : 1Q Results (Jan-Mar 2022)
PU
04/25Chugai Pharmaceutical Co., Ltd. - F. Hoffmann-La Roche Announces First Quarter Sales 20..
AQ
04/25CHUGAI PHARMACEUTICAL : Supplementary Materials for Consolidated Financial Results for the..
PU
More news
Analyst Recommendations on CHUGAI PHARMACEUTICAL CO., LTD
More recommendations
Financials
Sales 2022 1 187 B 9 282 M 9 282 M
Net income 2022 343 B 2 679 M 2 679 M
Net cash 2022 604 B 4 723 M 4 723 M
P/E ratio 2022 17,0x
Yield 2022 2,20%
Capitalization 5 815 B 45 478 M 45 478 M
EV / Sales 2022 4,39x
EV / Sales 2023 4,88x
Nbr of Employees 7 664
Free-Float 37,8%
Chart CHUGAI PHARMACEUTICAL CO., LTD
Duration : Period :
Chugai Pharmaceutical Co., Ltd Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends CHUGAI PHARMACEUTICAL CO., LTD
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 13
Last Close Price 3 536,00 JPY
Average target price 4 677,69 JPY
Spread / Average Target 32,3%
EPS Revisions
Managers and Directors
Tatsuro Kosaka Manager-Pharmaceutical Business Strategy Office
Osamu Okuda Manager-Life Cycle Management II
Itagaki Toshiaki CFO, Manager-Information Technology & Accounting
Hisafumi Okabe Senior Executive Officer & Head-Research
Junichi Nezu Executive Officer, GM-Research & Development
Sector and Competitors
1st jan.Capi. (M$)
CHUGAI PHARMACEUTICAL CO., LTD-5.33%45 478
JOHNSON & JOHNSON1.68%465 705
PFIZER, INC.-11.14%294 404
ELI LILLY AND COMPANY8.19%269 013
ABBVIE INC.11.53%266 851
ROCHE HOLDING AG-15.67%266 707